Current stock page

Stock Analysis

Axsome Therapeutics, Inc. (AXSM) Stock Analysis

Axsome Therapeutics, Inc. (AXSM) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

AXSM Stock Analysis Summary

Axsome Therapeutics, Inc. (AXSM) currently has an AIQ Score of 47/100, indicating a bearish setup. Value is the strongest factor at 65/100. Momentum is the weakest current factor at 24/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

AXSM at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$141.69
AIQ Score47/100
Overall ViewBearish
Technical Analysis ConsensusSell
Market Cap$7.43B
P/E Ratio (TTM)-46.3
Forward P/E—
EPS (Q3 FY2026)-$0.25
Revenue (Q3 FY2026)$259.69M
Dividend Yield (TTM)0.00%
Beta0.66
Volume973.07K
52-week range$123.00-$260.19
RSI 1440.79
50-Day SMA$171.45
200-Day SMA$197.05
Analyst Price Target$260.14
Next EarningsFeb 22, 2027
As of Nov 13, 2026 · Market close

AXSMAxsome Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 3/10
$141.69−$2.68 (−1.86%)

Latest quote

  • Momentum
    24
  • Value
    65
  • Quality
    57
  • Risk resilience
    57
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

AXSM Stock Analysis Summary

Axsome Therapeutics, Inc. (AXSM) currently has an AIQ Score of 47/100, indicating a bearish setup. Value is the strongest factor at 65/100. Momentum is the weakest current factor at 24/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, AXSM has AIQ Score of 47/100 with Value base of 65/100 and fading Momentum at 24/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Value (65/100) leads while Momentum (24/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -1.86% stock move · AXSM classified in Biotechnology.

Current Evidence

BearishAXSM is in a bearish AIQ regime; Value is the strongest visible factor at 65/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is AXSM Bullish or Bearish Right Now?

AXSM currently has a bearish overall setup. Value is the strongest factor at 65/100, while Momentum is weakest at 24/100. The current evidence suggests a bearish setup.

Bull Case
  • - Analyst target implies +83.60% upside from the latest quote.
Bear Case
  • - Momentum is weak at 24/100.
  • - Price is -28.09% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (29 vs 8).

Current Consensus

AXSM's Technical Analysis Consensus is currently Sell, with 8 buy, 9 neutral, and 29 sell votes. AXSM's 14-day RSI is 40.79, which places the stock in a weaker momentum range. AXSM's beta is 0.66, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in AXSM?

The largest recent change in AXSM is Value moving down by 1.0 points over the available 7-day comparison window. Value remains the strongest visible factor.

AIQ Score
+0.0
Momentum
+0.0
Quality
+1.0
Risk
-1.0

What Would Change the AXSM Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

AXSM Decision Framework

Public evidence layers, setup checks, and risk context for Axsome Therapeutics, Inc..

Axsome Therapeutics, Inc. (AXSM) Stock Analysis

Axsome Therapeutics, Inc. has an AIQ Score of 47/100 in a Bearish regime. Value is strongest at 65/100. Beta is 0.66, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextAXSM is in a Bearish AIQ regime with score 47/100.
Signal ConflictThe primary conflict is that value leads at 65/100 while momentum lags at 24/100.
Factor EvidenceMomentum 24/100 · Value 65/100 · Quality 57/100 · Risk 57/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Value is the strongest factor at 65/100.

TimingFail

Momentum is 24/100 and RSI (14) is 40.8.

Regime fitFail

AXSM is in a Bearish regime at 47/100.

Risk controlWait

Risk factor is 57/100 with beta 0.66 and annual volatility 45.79%.

ConflictWait

Current conflict: value leads at 65/100 while momentum lags at 24/100.

AIQ Score
47/100
Price
$141.69
Beta
0.66
RSI (14)
40.8

AXSM Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

AXSM Fundamentals

AXSM valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$259.69M
Net income
-$12.88M
Free cash flow
-$9.67M
View full AXSM fundamental analysis

AXSM Technical Analysis

AXSM technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Sell
RSI 14
40.79
Price vs SMA-50
-17.36%
View full AXSM technical analysis

AXSM Stock Catalysts

Track AXSM earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 22, 2027
Analyst target
$260.14
News items
5
View AXSM earnings and stock catalysts

AXSM Dividend Analysis

AXSM dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View AXSM dividend history and analysis

AXSM Financial Data

AXSM revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$259.69M
EPS
-$0.25
Periods
8
View AXSM financials

AXSM Risk Analysis

AXSM volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.66
Risk score
57/100
1Y volatility
45.79%
View AXSM risk analysis

AXSM Stock News

AXSM stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read AXSM stock news

AXSM vs Biotechnology Peers

Current peer cohort: AXSM · BBIO · BCRX · BHVN · BLTE. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
AXSM
Current stock
47/10065/10024/10057/1000.245.79%Current
BBIO
BridgeBio Pharma, Inc.
64/10055/10069/10062/1000.5544.14%AXSM vs BBIO
BCRX
BioCryst Pharmaceuticals, Inc.
59/10086/10042/10055/1000.3648.06%AXSM vs BCRX
BHVN
Biohaven Ltd.
47/100—78/10035/100182.98%AXSM vs BHVN
BLTE
Belite Bio, Inc
74/100—71/10060/1000.953.71%AXSM vs BLTE
Pairwise Compare links: BBIO · BCRX · BHVN · BLTEAXSM vs BBIOAXSM vs BCRXAXSM vs BHVNAXSM vs BLTECompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a AXSM stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for AXSM: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-46.3
As of Nov 13, 2026
Revenue growth
51.87%
Gross margin
93.25%
Current debt / equity
2.07
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$259.69M
Quarter net income
-$12.88M
Quarter free cash flow
-$9.67M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Mixed
RSI 14
40.79
MACD
-8.3

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
57/100
Beta
0.66
Annual volatility
45.79%
Max drawdown
-49.13%

AXSM Stock FAQ

What is AXSM stock price today?

Axsome Therapeutics, Inc.'s current stock price is $141.69. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is AXSM bullish or bearish right now?

AXSM's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is AXSM's market cap?

AXSM's market cap is $7.43B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is AXSM's current P/E ratio?

AXSM's current P/E ratio is -46.3 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is AXSM's RSI?

AXSM's 14-day RSI is 40.79 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is AXSM above its 50-day and 200-day moving averages?

AXSM is -17.36% from its 50-day SMA and -28.09% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is AXSM's next earnings date?

AXSM's next earnings date is currently listed as Feb 22, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does AXSM pay a dividend?

AXSM's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.